Table 4Generalized anxiety disorder—PCTs contributing to meta-analysis

Author, YearSubjectsNTreatmentsDurationOutcomes
Pollack et al. 20068418-72 years old, DSM-IV GAD comorbid depression, dysthymia, and other anxiety disorders except for PTSD and OCD, if GAD was considered primary by the clinician and patient based on disorder severity and associated distress24Placebo

Olanzapine 2.5-20 mg/day
6 weeks% Responders on HAM-A:
Olanzapine vs Placebo – RR = 6.67 (0.93, 47.59)
Bandelow et al. 20098818-65 years old, diagnosed GAD, HAM-A total score >= 20 with item 1 and 2 scores >= 2, MADRS total score <= 16, CGI-S score >=4 at enrolment and randomization873Placebo

Quetiapine 50-150 mg/day

Quetiapine 50 mg/day

Paroxetine 20 mg/day
8 weeks% Responders on HAM-A:
Quetiapine vs Placebo - RR = 1.36 (1.17, 1.59)
Joyce et al. 200894Diagnosed GAD710Placebo

Quetiapine 50 mg/day

Quetiapine 150 mg/day
8 weeks% Responders on HAM-A:
Quetiapine vs Placebo - RR = 1.02 (0.85, 1.21)
Merideth et al. 200887DSM-IV diagnosis of GAD, HAM-A total score >=20 with item 1 and item 2 scores >=2, CGI-S >=4, MADRS <=16854Placebo

Escitalopram 10 mg/day

Quetiapine 150 mg/day

Quetiapine 300 mg/day
8 weeks% Responders on HAM-A:
Quetiapine vs Placebo - RR = 1.46 (1.21, 1.76)
Pandina et al. 20079915-65 years old, diagnosed GAD, CGI-S >=4, antidepressant, benzodiazepine, buspirone or a combination of an antidepressants plus benzodiazepine or buspirone for at least 8 weeks prior and stable × 4 weeks417Placebo 0.25-2 mg/day

Risperidone 0.25-2 mg/day
4 weeks% Responders on HAM-A:
Risperidone vs Placebo - RR = 0.99 (0.78, 1.25)

CGI-S = Clinical Global Impression Scale-Severity Subscale; DSM-IV = Diagnostic and Statistical Manual of Mental Disorders, 4th edition; GAD = generalized anxiety disorder; HAM-A = Hamilton Anxiety Rating Scale; MADRS = Montgomery-Asberg Depression Rating Scale; RR = relative risk

From: Results

Cover of Off-Label Use of Atypical Antipsychotics: An Update
Off-Label Use of Atypical Antipsychotics: An Update [Internet].
Comparative Effectiveness Reviews, No. 43.
Maglione M, Maher AR, Hu J, et al.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.